Navigation Links
Onyx Pharmaceuticals to Present at UBS Global Life Sciences Conference
Date:9/18/2007

EMERYVILLE, Calif., Sept. 18 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the UBS Global Life Sciences conference on Monday, September 24, at 9:00 a.m. Eastern Time. Interested parties may access a live webcast of the presentation at:

http://events.streamx.us/us/event/eventdetails.aspx?id=ubs20070924

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentation through October 27, 2007.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative therapies that target the molecular mechanisms that cause cancer. The company is developing Nexavar(R), a small molecule drug, with Bayer Pharmaceuticals Corporation. Nexavar has been approved for the treatment of advanced kidney cancer. For more information about Onyx's pipeline and activities, visit the company's web site at: http://www.onyx-pharm.com.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... Washington, USA (PRWEB) , ... January 11, 2017 ... ... SPIE, the international society for optics and photonics , are commending the U.S. ... photonics, following the signing Friday by the President of the American Innovation and ...
(Date:1/11/2017)... Francisco, CA (PRWEB) , ... January 11, 2017 ... ... series of in-kind scientific grants to ground-breaking microbiome studies. Its most recent microbiome ... School of Medicine, who will study the effect of long-term use of oral ...
(Date:1/11/2017)... ... January 11, 2017 , ... Back pain relief technology ... Shots and No Surgery for positive back pain relief for WAR members. , This ... worldwide and could be life changing for millions suffering from chronic back pain. , ...
(Date:1/11/2017)...  GenVec, Inc. (NASDAQ: GNVC ), ... its chief scientific officer, Douglas E. Brough ... for translational development of innovative gene and cell ... Phacilitate Cell & Gene Therapy World 2017 Conference ... Brough,s presentation will highlight the utility of the ...
Breaking Biology Technology:
(Date:12/15/2016)... 2016 "Increase in mobile transactions is driving ... biometrics market is expected to grow from USD 4.03 ... at a CAGR of 29.3% between 2016 and 2022. ... growing demand for smart devices, government initiatives, and increasing ... component is expected to grow at a high rate ...
(Date:12/7/2016)... 2016 According to a new market research report "Emotion ... Expression, Voice Recognition), Service, Application Area, End User, And Region - Global Forecast ... USD 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a ... Reading ... MarketsandMarkets Logo ...
(Date:12/6/2016)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the ... €500.0 million principal amount of its 1.414% senior unsecured notes ... senior unsecured notes due 2026. The closing ... subject to the satisfaction of customary closing conditions.  The notes ... The Company intends to use the net proceeds ...
Breaking Biology News(10 mins):